Side Effects are Limiting GLP-1 Drug Efficacy: How Can Personalization Offer a Solution?

By integrating digitization and machine learning, there is an opportunity to deliver personalized care to all patients and scale precision dosing with minimal physician involvement, maximizing the effectiveness and accessibility of these drugs. The post Side Effects are Limiting GLP-1 Drug Efficacy: How Can Personalization Offer a Solution? appeared first on MedCity News.

Read More

FDA Rejection Delays Regeneron From Competing With J&J, Pfizer in Multiple Myeloma

Regeneron Pharmaceuticals said the FDA cited no approvability concerns for its multiple myeloma drug, linvoseltamab, other than previously identified issues with a contract manufacturer. While linvoseltamab trails bispecific antibodies currently marketed by Johnson & Johnson and Pfizer, if approved, it could bring patients an earlier treatment option. The post FDA Rejection Delays Regeneron From Competing…

Read More